血压药物可能改善溃疡性结肠炎疗法
Blood pressure meds may improve therapy for ulcerative colitis
一项新研究发现,高血压药物可能增强溃疡性结肠炎药物vedolizumab的疗效,减少患者住院和手术风险。研究团队分析了1300多名患者的临床数据,发现使用ACE抑制剂或ARB类药物的患者住院和手术风险较低。
研究发现血压药物可能增强溃疡性结肠炎治疗效果,为该病治疗提供了新思路。
A class of blood pressure medications may improve a widely used treatment for ulcerative colitis, the most common type of inflammatory bowel disease, suggests a new study, led by Northwestern Medicine and Kiel University in Germany, of thousands of patients with the disease.
The study found that those taking the blood pressure meds for hypertension alongside the ulcerative colitis drug vedolizumab (brand name Entyvio) were less likely to experience serious complications resulting in hospitalization and surgery to remove the colon.
The findings are published in Nature Medicine.
Ulcerative colitis, a chronic condition that causes inflammation and sores in the colon, affects over 1 million people in the U.S. and often begins in adolescence or young adulthood. Despite the emergence of advanced and expensive therapies, such as vedolizumab, most patients with ulcerative colitis do not achieve lasting remission with available treatments.
"You're talking about teens or young adults who are suffering from uncontrollable diarrhea, bloody stool and an inability to function at school, work, or go out and have normal social interactions," said study senior author Dr. Parambir Dulai, associate professor of medicine in the division of gastroenterology and hepatology at Northwestern University Feinberg School of Medicine.
"And the psychosocial and physical impact of the disease is substantial, to the point where it may be on par with cancer in terms of the impact," Dulai added. "Finding a new pathway where we have the potential to repurpose an inexpensive, generic, readily available medication could offer a tremendous reprieve for a lot of these young adults who are suffering on a daily basis."
How the study was conducted
Dulai, Dr. Stefan Schreiber of Kiel University and their colleagues analyzed data from more than 1,300 patients enrolled in two clinical trials of vedolizumab for ulcerative colitis. By tracking how symptoms (stool frequency and rectal bleeding) changed over time in the trial participants, the scientists were able to identify different patterns of response to the drug.
Next, to understand the biology behind treatment resistance, the research team analyzed tissue biopsies and blood samples to measure gene and protein activity—and made two key discoveries.
First, they found that poor response to vedolizumab was linked to a form of inflammation involving blood vessels in the colon. Second, they discovered that this inflammation was linked to a biological pathway that is already targeted by common blood pressure drugs known as ACE inhibitors and angiotensin receptor blockers, or ARBs.
Finally, to explore whether the blood pressure drugs could enhance the effectiveness of vedolizumab, the scientists analyzed health care data from nearly 9,000 ulcerative colitis patients who also had high blood pressure (hypertension). Among patients on vedolizumab, those taking ACE inhibitors or ARBs were less likely to be hospitalized or require surgery.
Other blood pressure drug classes examined did not show the same association. The benefits were also specific to vedolizumab as patients taking ACE inhibitors or ARBs alongside other ulcerative colitis medications saw no difference.
Next steps
The study authors say clinical trials are now needed to confirm their findings and to understand how they might be applied to patients who have normal blood pressure.
"We don't know yet if you can use antihypertensive medications in normotensive patients. People who have normal blood pressure, you don't want to give them a medicine to drop their blood pressure," said Dulai, who also is a Northwestern Medicine physician and a member of the Center for Human Immunobiology at Feinberg.
"There may be other ways to target that same pathway without the other effects that are present from blood pressure medications."
"In other words, our study offers a rationale to start thinking about developing drugs specifically for this," Dulai said.
Dulai said his team is also working on developing a diagnostic test based on the biological markers they discovered in those who didn't respond to vedolizumab. Such a test could allow clinicians to identify, ahead of time, patients who are either likely to respond well to treatment or who would be better suited for alternatives.
That level of foresight could be crucial for "many patients who are starting these medications and are suffering from ongoing symptoms for months before they get any reprieve from finding a medication that works for them," Dulai said.
Publication details
Stefan Schreiber et al., An ulcerative colitis taxonomy defined by individual patient-reported response trajectories, Nature Medicine (2026). DOI: 10.1038/s41591-026-04741-8
Journal information: Nature Medicine
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Blood pressure meds may improve therapy for ulcerative colitis (2026, November 10) retrieved 10 November 2026 from https://medicalxpress.com/news/2026-11-blood-pressure-meds-therapy-ulcerative.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com